|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2003-2-13
|
|
pubmed:abstractText |
Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the clinical significance of these antibodies in patients with Crohn's disease.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2003 Massachusetts Medical Society
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
13
|
|
pubmed:volume |
348
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
601-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12584368-Adolescent,
pubmed-meshheading:12584368-Adult,
pubmed-meshheading:12584368-Aged,
pubmed-meshheading:12584368-Antibodies,
pubmed-meshheading:12584368-Antibodies, Monoclonal,
pubmed-meshheading:12584368-Crohn Disease,
pubmed-meshheading:12584368-Female,
pubmed-meshheading:12584368-Gastrointestinal Agents,
pubmed-meshheading:12584368-Humans,
pubmed-meshheading:12584368-Immunosuppressive Agents,
pubmed-meshheading:12584368-Infusions, Intravenous,
pubmed-meshheading:12584368-Male,
pubmed-meshheading:12584368-Middle Aged,
pubmed-meshheading:12584368-Risk Factors,
pubmed-meshheading:12584368-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
|
|
pubmed:affiliation |
Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
